We are pleased to announce that Cardiolink has recently concluded a distribution agreement with Exthera Medical Corporation, a medical device company focused on therapeutic applications to treat drug-resistant and drug-susceptible bloodstream infections in high-risk patient populations, regarding its microbind affinity blood filter Seraph^® 100.

Seraph 100 is a single use extracorporeal broadspectrum sorbent hemoperfusion device indicated for the reduction of pathogens from the bloodstream in adjunction to antibiotic treatment during BSI (blood-stream infections). Seraph 100 has been designed to safely and effectively treat bacterial, fungal, and viral bloodstream infections for both drug-resistant and drug-susceptible pathogens.

You can read the full features and indications of Seraph 100 at the following link.